1. Medicines
  2. Rheumatology
  3. COSENTYX® (secukinumab)
  4. Why Cosentyx in axSpA?

Click here for Prescribing Information

Why Cosentyx in axSpA?

Why Cosentyx in axSpA?

Dive into the data below to see how Cosentyx could help your patients with axSpA

Cosentyx_AxSpA_HCP

 

Take the next step

We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.

Or find out more using the links below...

  1. Cosentyx (secukinumab) Summary of Product Characteristics. Available at www.medicines.ie. Accessed November 2024
  2. Marzo-Ortega H et al. Arthritis Rheumatol. 2019;71(suppl 10). Abstract 1504.
  3. Baraliakos X et al. RMD Open. 2019;5(2):e001005.
  4. Baeten D et al. N Engl J Med. 2015;373(26):2534-2548.
  5. Novartis data on file. CAIN457F2310 Data Analysis Report. June 2019.
  6. Novartis data on file. CAIN457F2310 (MEASURE 2): Nocturnal Back Pain. January 2020.
  7. Marzo-Ortega H et al. Arthritis Care Res. 2017;69(7):1020-1029 and Supplementary Tables.
  8. Deodhar A et al. Clin Exp Rheumatol. 2019;37(2):260-269.
  9. Taurog JD et al. N Engl J Med. 2016; 375(13):1303.
  10. Zochling J. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S47-S58.
  11. Novartis data on file. CAIN457F2310 (MEASURE 2): Nocturnal Back Pain. February 2021.
  12. Zochling J. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S47-S58.
  13. Braun J et al. Rheumatology (Oxford). 2019;58(5):859-868.
Rate this content: 
No votes yet
IE271483-1 | November 2024
Rheumatology
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie.. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.